Sastasundar Ventures
298.25
-1.45(-0.48%)
Market Cap₹948.75 Cr
PE Ratio-105.28
Company Performance:
1D-0.48%
1M-6.67%
6M+6.67%
1Y+4.21%
5Y+144.67%
View Company Insightsright
More news about Sastasundar Ventures
18Nov 25
Luv Kush Projects Boosts Stake in Sastasundar Ventures
Luv Kush Projects Limited, a promoter group entity of Sastasundar Ventures Limited, acquired 20,000 equity shares worth Rs. 8,06,748.29 through a market purchase on November 17, 2025. This transaction increased their shareholding from 11.8993% to 11.9622%. The company promptly disclosed this transaction in compliance with SEBI regulations. Another promoter, Banwari Lal Mittal, also acquired 20,000 shares on the same day, increasing his stake from 33.37% to 33.4355%. Sastasundar Ventures recently hosted an Earnings Conference Call discussing their performance for the quarter and half year ended September 30, 2025.
 no imag found
13Nov 25
Sastasundar Ventures Narrows Q2 Loss Despite Revenue Growth
Sastasundar Ventures Limited reported a consolidated net loss of 127.00 million rupees in Q2, an 88% reduction from the 1.09 billion rupees loss in the same period last year. Revenue increased by 9.9% to 3.00 billion rupees. The company is expanding operations beyond West Bengal, focusing on product expansion, implementing a 'Quick Health Initiative', strengthening backend infrastructure, and integrating AI across its value chain.
 no imag found
12Nov 25
Sastasundar Ventures' Stake in Healthbuddy Subsidiary Rises to 78.89% Post Buyback
Sastasundar Ventures Limited has increased its stake in its material subsidiary, Sastasundar Healthbuddy Limited (SHBL), from 72.14% to 78.89% following a buyback offer. SHBL bought back 20,27,534 equity shares from Mitsubishi Corporation at Rs. 493.21 per share, with a total consideration not exceeding Rs. 100 crore. SHBL, incorporated in 2011, is involved in wholesale trading of medicinal products and healthcare goods, with a turnover of Rs. 1,08,498.21 lacs in the most recent fiscal year.
 no imag found
19Sept 25
Sastasundar Healthbuddy Approves Rs 100 Crore Share Buyback at Rs 493.21 Per Share
Sastasundar Healthbuddy Limited (SHBL), a material subsidiary of Sastasundar Ventures, has approved a share buyback program. The company plans to repurchase 20,27,534 fully paid-up equity shares at ₹493.21 per share, totaling ₹100 crore. The buyback is subject to shareholder approval. In response, Sastasundar Ventures has closed the trading window for designated persons and their immediate relatives, in compliance with SEBI regulations.
 no imag found
16Aug 25
SastaSundar Ventures Reports Mixed Q1 Results: B2B Growth Offsets B2C Decline
Sastasundar Ventures Limited reported a 5.9% YoY increase in total revenue to ₹278.50 crores for Q1. The B2B segment, RetailerShakti, grew by 30.9% to ₹244.50 crores, while the B2C segment, SastaSundar, declined by 55.7% to ₹33.30 crores. Financial Services revenue surged 168.9% to ₹19.90 crores. EBITDA was -₹13.80 crores, and PAT decreased by 35.1% to ₹26.60 crores. The company maintains a strong balance sheet with ₹974.40 crores in total assets, including ₹655.00 crores in liquid assets. Working capital management improved with inventory days reducing from 40 to 36 days. However, operating cash flow was negative at -₹17.30 crores, indicating ongoing operational challenges.
 no imag found
12Aug 25
Sastasundar Ventures Reports Robust Q1 Profit, Driven by Strong Healthcare Network Performance
Sastasundar Ventures Limited reported a consolidated net profit of Rs. 2,659.21 crore in Q1, a significant improvement from last year's loss. Total revenue from operations stood at Rs. 298.43 crore. The Healthcare Network segment contributed Rs. 278.54 crore to revenue but reported a loss, while the Financial Services segment generated Rs. 19.89 crore in revenue with a profit. On a standalone basis, the company reported a revenue of Rs. 9.67 lakh and a reduced net loss of Rs. 10.95 lakh. The Board of Directors also reviewed and amended the company's fair disclosure practices code.
 no imag found
30May 25
SASTASUNDAR VENTURES Reports Decline in Q4 Profit and Revenue
SASTASUNDAR VENTURES released its Q4 consolidated financial results, showing a decline in both profit and revenue. Net profit decreased by 16.46% to ₹137.00 crore from ₹164.00 crore in the previous year. Revenue fell by 7.17% to ₹285.00 crore from ₹307.00 crore year-over-year.
 no imag found
Sastasundar Ventures
298.25
-1.45
(-0.48%)
1 Year Returns:+4.21%
Industry Peers
Dr. Lal Path Labs
1,443.40
(+2.30%)
Metropolis Healthcare
1,986.90
(+0.73%)
Krsnaa Diagnostics
700.80
(-2.76%)
Suraksha Diagnostic
288.35
(+0.82%)
3B BlackBio DX
1,627.55
(+1.80%)
Sastasundar Ventures
298.25
(-0.48%)